Live feed08:00:00·677dPRReleasevia QuantisnowTempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control ArmByQuantisnow·Wall Street's wire, on your screen.TPST· Tempest Therapeutics Inc.Health Care
